Thermo Fisher Scientific
Private Company
Funding information not available
Overview
Thermo Fisher Scientific's mission is to enable its customers to make the world healthier, cleaner, and safer by providing the scientific tools and services that accelerate innovation. The company has achieved a dominant market position through strategic acquisitions, organic innovation, and the creation of an unparalleled, integrated ecosystem for the scientific community. Its strategy revolves around leveraging its scale and breadth to drive operational excellence, investing in high-growth areas like bioproduction and precision medicine, and selectively advancing an internal pipeline of novel therapeutics. With a market capitalization exceeding $178 billion, Thermo Fisher is a foundational pillar of the global life sciences industry.
Technology Platform
A comprehensive, industry-leading suite of platforms spanning high-resolution mass spectrometry (Orbitrap), next-generation sequencing (Ion Torrent), cell culture and gene editing (Gibco, Invitrogen), chromatography, electron microscopy (including cryo-EM), and integrated biopharma production services.
Pipeline
9| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Tolvaptan + placebo | Acute Heart Failure | Phase 3 | |
| zamtocabtagene autoleucel (MB-CART2019.1) | B-Cell Neoplasm | Phase 2 | |
| BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 ... | Diabetes Mellitus | Phase 2 | |
| LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg)... | Diffuse Large B-cell Lymphoma | Phase 1/2 | |
| ShA9 Topical Gel + Hydrocortisone Ointment + Clobetasol Oint... | Atopic Dermatitis | Phase 1 |